An Enhanced Cancer Immunogenic Cell Death Strategy: Fibrate-Oxaliplatin(IV) Conjugates with Modulating Tumor Immune Microenvironment
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.5c02436 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Xue-Jiao Liang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Medicinal Chemistry and Molecular Diagnosis of Ministry of Education, Key Laboratory of Pharmaceutical Quality Control of Hebei Pro…. Hauptthemen laut MEDLINE: Oxaliplatin, Tumor Microenvironment, Immunogenic Cell Death, Antineoplastic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 78 Literaturangaben. Gefördert von: Natural Science Foundation of Hebei Province, Hebei University, National Natural Science Foundation of China.
Abstract (Originalsprache)
The present immunogenic cell death (ICD) strategies remain far from being suitable for effective clinical applications, highlighting the urgent need for novel strategies. Herein, the oxaliplatin-like fibrate-derived platinum(IV) conjugates 2–7 were designed and synthesized to explore novel approaches for enhancing ICD via modulation of tumor microenvironment (TME). Bioactivity evaluations showed that these conjugates accumulated highly in cells and released active components, exerting cytotoxicity. Especially, 5 exhibited 319-fold higher cytotoxicity than oxaliplatin. Mechanistic studies revealed that these conjugates induced severe DNA damage, mitochondrial dysfunction, and endoplasmic reticulum stress, ultimately activating the apoptotic pathway. Importantly, these events interacted with cholesterol metabolic regulation to form a self-amplifying cycle, which substantially enhanced damage-associated molecular pattern release to strengthen ICD and further modulated the TME by promoting CD8+ T cell infiltration and cytokine secretion while downregulating PD-L1 expression and Treg-mediated immunosuppression. In vivo, these conjugates exhibited favorable biocompatibility, potent antitumor activity and reduced toxicity compared to oxaliplatin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Medicinal Chemistry and Molecular Diagnosis of Ministry of Education, Key Laboratory of Pharmaceutical Quality Control of Hebei Province, College of Pharmacy, Hebei University, Baoding, Hebei 071002, P…
ORCID-Profile: Zhihao You, Yali Song, Longfei Li, Xue-Qing Song
Förderung
- Natural Science Foundation of Hebei Province
- Hebei University
- National Natural Science Foundation of China
- Hebei Provincial Department of Science and Technology
Zitieren
APA
Liang, X. J., Guo, X., Zhu, P. H., Zhao, Z. H., You, Z., Yang, K., Song, Y., Li, L., & Song, X. Q. (2025). An Enhanced Cancer Immunogenic Cell Death Strategy: Fibrate-Oxaliplatin(IV) Conjugates with Modulating Tumor Immune Microenvironment. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c02436
Vancouver
Liang XJ, Guo X, Zhu PH, Zhao ZH, You Z, Yang K, et al. An Enhanced Cancer Immunogenic Cell Death Strategy: Fibrate-Oxaliplatin(IV) Conjugates with Modulating Tumor Immune Microenvironment. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c02436
BibTeX
@article{Liang2025,
author = {Liang, Xue-Jiao and Guo, Xu and Zhu, Peng-Hui and Zhao, Zi-Han and You, Zhihao and Yang, Kan and Song, Yali and Li, Longfei and Song, Xue-Qing},
title = {An Enhanced Cancer Immunogenic Cell Death Strategy: Fibrate-Oxaliplatin(IV) Conjugates with Modulating Tumor Immune Microenvironment},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.5c02436}
}
EUVIMED